Endoscopy 2021; 53(02): 123-132
DOI: 10.1055/a-1203-5930
Original article

Argon plasma coagulation for Barrett’s esophagus with low-grade dysplasia: a randomized trial with long-term follow-up on the impact of power setting and proton pump inhibitor dose

Ewa Wronska
1  Department of Gastroenterology, Hepatology and Oncology, Center of Postgraduate Medical Education, Warsaw, Poland
2  Department of Gastroenterological Oncology, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland
,
Marcin Polkowski
1  Department of Gastroenterology, Hepatology and Oncology, Center of Postgraduate Medical Education, Warsaw, Poland
2  Department of Gastroenterological Oncology, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland
,
Janina Orlowska
2  Department of Gastroenterological Oncology, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland
,
Andrzej Mroz
3  Department of Pathomorphology, Center of Postgraduate Medical Education, Warsaw, Poland
4  Department of Pathology and Laboratory Medicine, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland
,
Paulina Wieszczy
1  Department of Gastroenterology, Hepatology and Oncology, Center of Postgraduate Medical Education, Warsaw, Poland
5  Department of Cancer Prevention, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland
,
Jaroslaw Regula
1  Department of Gastroenterology, Hepatology and Oncology, Center of Postgraduate Medical Education, Warsaw, Poland
2  Department of Gastroenterological Oncology, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland
› Author Affiliations
Trial Registration: ClinicalTrials.gov Registration number (trial ID): NCT0415474 Type of study: prospective, randomized study


Abstract

Background This study evaluated the impact of power setting and proton pump inhibitor (PPI) dose on efficacy and safety of argon plasma coagulation (APC) of Barrett’s esophagus (BE) with low-grade dysplasia (LGD).

Methods 71 patients were randomized to APC with power set at 90 W or 60 W followed by 120 mg or 40 mg omeprazole. The primary outcome was the rate of complete (endoscopic and histologic) ablation of BE at 6 weeks. Secondary outcomes included safety and long-term efficacy.

Results Complete ablation rate in the 90 W/120 mg, 90 W/40 mg, and 60 W/120 mg groups was 78 % (18/23; 95 % confidence interval [CI] 61–95), 60 % (15/25; 95 %CI 41–79), 74 % (17/23; 95 %CI 56–92), respectively, at 6 weeks and 70 % (16/23; 95 %CI 51–88), 52 % (13/25; 95 %CI 32–72), and 65 % (15/23; 95 %CI 46–85) at 2 years post-treatment (differences not significant). Additional APC was required in 28 patients (23 residual and 5 recurrent BE). At median follow-up of 108 months, 66/71 patients (93 %; 95 %CI 87–99) maintained complete ablation. No high-grade dysplasia or adenocarcinoma developed. Overall, adverse events (97 % mild) did not differ significantly between groups. Chest pain/discomfort was more frequent in patients receiving 90 W vs. 60 W power (P < 0.001). One patient had esophageal perforation and two developed stenosis.

Conclusions APC power setting and PPI dose did not impact efficacy and safety of BE ablation. Complete ablation of BE with LGD was durable in > 90 % of patients, without any evidence of neoplasia progression in the long term.



Publication History

Received: 19 December 2019

Accepted: 26 May 2020

Publication Date:
10 July 2020 (online)

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany